PSMA ligands and uses thereof

Patent metadata

Field	Value
Publication number	US-10363313-B2
Application number	US-201815895855-A
Country	US
Kind code	B2
Filing date	Feb 13, 2018
Priority date	Feb 15, 2013
Publication date	Jul 30, 2019
Grant date	Jul 30, 2019

Abstract

Compounds that are PSMA ligands, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.

First claim

Having described the invention, we claim:

1. A method of treating cancer in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound having the following formula (I):

wherein:
n and n 1 are each independently 1, 2, 3, or 4;
L comprises at least one ring selected from the group consisting of an optionally substituted 4 to 7 membered nonaromatic heterocyclic ring and an optionally substituted C4-C7 cycloalkyl ring;
B comprises at least one glutamic acid residue; and

Y is a H of B or includes at least one of a detectable moiety, therapeutic agent, or a theranostic agent that is directly or indirectly linked to B.

2. The method of claim 1 , wherein Y is selected from the group consisting of an imaging agent, anticancer agent, or combination thereof.

3. The method of claim 1 , wherein B has the following formula:

wherein m is 1, 2, 3, or 4, X 1 is an amino acid, and Y 1 is a H of X 1 or includes at least one of an amino acid, peptide, detectable moiety, therapeutic agent, or theranostic agent that is directly or indirectly linked to X 1 .

4. The method of claim 1 , the compound having the general formula:

wherein m, n, and n 1 is 1, 2, 3, or 4; n and n 1 are each independently 1, 2, 3, or 4; and Y 2 is a H or includes at least one of an amino acid, peptide, detectable moiety, therapeutic agent, or theranostic agent.

5. The method of claim 1 , wherein Y is a (PEGylated) nanoparticle that is directly or indirectly linked to B, and at least one anti-cancer agent coupled to the surface of the nanoparticle.

6. The method of claim 5 , wherein the anti-cancer agent comprising Phthalocyanine 4.

7. The method of claim 1 , wherein the compound has the following formula:

8. The method of claim 1 , wherein the compound has the following formula:

9. The method of claim 1 , wherein the compound has the following formula:

Assignees

• Univ Case Western Reserve

Inventors

• Basilion James
• Wang Xinning
• Burda Clemens

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K49/0052

  Small organic molecules (oligomers, polymers, dendrimers A61K49/0054) · CPC title

• A61K41/0071

  PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines · CPC title

• A61N5/062

  Photodynamic therapy, i.e. excitation of an agent · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title